Global Telmisartan Market Booming Worldwide with Latest Trend and Future Scope by 2028

The global telmisartan market is expected to grow at a CAGR of 3.5% during the forecast period (2022-2028). Telmisartan is a non-peptide angiotensin receptor blocker (ARB) used to treat hypertension and lower the risk of cardiovascular disease. It can be taken alone or in combination with other medications such as hydrochlorothiazide and amlodipine. Telmisartan comes in three different strengths, such as 20 mg, 40 mg, and 80 mg tablets. This drug is used to treat mild to moderate hypertension. It works by allowing blood to flow more freely by relaxing blood vessels. However, it can cause dizziness, cough, lightheadedness, sinus pain, and other side effects.

The market is expected to grow significantly owing to an increase in the prevalence of high blood pressure (hypertension), rising geriatric population, and an increase in government initiatives to raise awareness about blood pressure. For instance, in May 2017, the Argentinian Society of Hypertension (SAHA) participated in campaigns such as “May Measurement Month & World Hypertension Day” to raise public awareness about hypertension and its treatment. Furthermore, the telmisartan market is expected to grow owing to an increase in marketing approvals for generic versions of the drug, an increase in sedentary lifestyles, and significant rise in the incidence of chronic diseases such as diabetes and kidney disease. Asia-Pacific presents lucrative opportunities for key players operating in the telmisartan market, owing to an increase in the number of hypertension patients, increased adoption of antihypertensive drugs, development of the R&D in pharmaceutical sector, and rise in healthcare reforms.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Indication
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Abbott Laboratories, GlaxoSmithKline Plc (GSK), and Mylan N.V., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impact the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Telmisartan Market Report by Segment

By Indication

• Hypertension
• Cardiovascular Risk Reduction

By Distribution Channel

• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies
• Online Pharmacies